Cargando…

Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy

OBJECTIVES: To evaluate the results of salvage conformal radiation therapy (3DC-EBRT) for patients submitted to radical prostatectomy (RP) who have achieved complete PSA response and who have never been treated with hormonal therapy (HT). To present the results of biochemical control, a period free...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacinto, Alexandre A, Fede, Angelo BS, Fagundes, Lívia A, Salvajoli, João V, Castilho, Marcus S, Viani, Gustavo A, Fogaroli, Ricardo C, Novaes, Paulo ERS, Pellizzon, Antonio Cássio A, Maia, Maria AC, Ferrigno, Robson
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820601/
https://www.ncbi.nlm.nih.gov/pubmed/17316430
http://dx.doi.org/10.1186/1748-717X-2-8
_version_ 1782132639319195648
author Jacinto, Alexandre A
Fede, Angelo BS
Fagundes, Lívia A
Salvajoli, João V
Castilho, Marcus S
Viani, Gustavo A
Fogaroli, Ricardo C
Novaes, Paulo ERS
Pellizzon, Antonio Cássio A
Maia, Maria AC
Ferrigno, Robson
author_facet Jacinto, Alexandre A
Fede, Angelo BS
Fagundes, Lívia A
Salvajoli, João V
Castilho, Marcus S
Viani, Gustavo A
Fogaroli, Ricardo C
Novaes, Paulo ERS
Pellizzon, Antonio Cássio A
Maia, Maria AC
Ferrigno, Robson
author_sort Jacinto, Alexandre A
collection PubMed
description OBJECTIVES: To evaluate the results of salvage conformal radiation therapy (3DC-EBRT) for patients submitted to radical prostatectomy (RP) who have achieved complete PSA response and who have never been treated with hormonal therapy (HT). To present the results of biochemical control, a period free from hormonal therapy and factors related to its prognosis. MATERIALS AND METHODS: from August 2002 to December 2004, 43 prostate cancer patients submitted to RP presented biochemical failure after achieving a PSA < 0.2 ng/ml. They have never received HT and were submitted to salvage 3DC-EBRT. Median age was 62 years, median preoperative PSA was 8.8 ng/ml, median Gleason Score was 7. Any PSA rise above 0.2 was defined as biochemical failure after surgery. Median 3DC-EBRT dose was 70 Gy, biochemical failure after EBRT was defined as 3 consecutive rises in PSA or a single rise enough to trigger HT. RESULTS: 3-year biochemical non-evidence of disease (BNED) was 71%. PSA doubling time lower than 4 months (p = 0.01) and time from recurrence to salvage EBRT (p = 0.04) were associated with worse chance of biochemical control. Biochemical control of 76% was achieved when RT had been introduced with a PSA lower than 1 ng/ml vs. 48% with a PSA higher than 1 (p = 0.19). Late toxicity was acceptable. CONCLUSION: 70% of biochemical control in 3 years can be achieved with salvage radiotherapy in selected patients. The importance of PSADT was confirmed in this study and radiotherapy should be started as early as possible. Longer follow up is necessary, but it is possible to conclude that a long interval free from hormonal therapy was achieved with low rate of toxicity avoiding or at least delaying several important adverse effects related to hormonal treatment.
format Text
id pubmed-1820601
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18206012007-03-10 Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy Jacinto, Alexandre A Fede, Angelo BS Fagundes, Lívia A Salvajoli, João V Castilho, Marcus S Viani, Gustavo A Fogaroli, Ricardo C Novaes, Paulo ERS Pellizzon, Antonio Cássio A Maia, Maria AC Ferrigno, Robson Radiat Oncol Research OBJECTIVES: To evaluate the results of salvage conformal radiation therapy (3DC-EBRT) for patients submitted to radical prostatectomy (RP) who have achieved complete PSA response and who have never been treated with hormonal therapy (HT). To present the results of biochemical control, a period free from hormonal therapy and factors related to its prognosis. MATERIALS AND METHODS: from August 2002 to December 2004, 43 prostate cancer patients submitted to RP presented biochemical failure after achieving a PSA < 0.2 ng/ml. They have never received HT and were submitted to salvage 3DC-EBRT. Median age was 62 years, median preoperative PSA was 8.8 ng/ml, median Gleason Score was 7. Any PSA rise above 0.2 was defined as biochemical failure after surgery. Median 3DC-EBRT dose was 70 Gy, biochemical failure after EBRT was defined as 3 consecutive rises in PSA or a single rise enough to trigger HT. RESULTS: 3-year biochemical non-evidence of disease (BNED) was 71%. PSA doubling time lower than 4 months (p = 0.01) and time from recurrence to salvage EBRT (p = 0.04) were associated with worse chance of biochemical control. Biochemical control of 76% was achieved when RT had been introduced with a PSA lower than 1 ng/ml vs. 48% with a PSA higher than 1 (p = 0.19). Late toxicity was acceptable. CONCLUSION: 70% of biochemical control in 3 years can be achieved with salvage radiotherapy in selected patients. The importance of PSADT was confirmed in this study and radiotherapy should be started as early as possible. Longer follow up is necessary, but it is possible to conclude that a long interval free from hormonal therapy was achieved with low rate of toxicity avoiding or at least delaying several important adverse effects related to hormonal treatment. BioMed Central 2007-02-22 /pmc/articles/PMC1820601/ /pubmed/17316430 http://dx.doi.org/10.1186/1748-717X-2-8 Text en Copyright © 2007 Jacinto et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Jacinto, Alexandre A
Fede, Angelo BS
Fagundes, Lívia A
Salvajoli, João V
Castilho, Marcus S
Viani, Gustavo A
Fogaroli, Ricardo C
Novaes, Paulo ERS
Pellizzon, Antonio Cássio A
Maia, Maria AC
Ferrigno, Robson
Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
title Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
title_full Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
title_fullStr Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
title_full_unstemmed Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
title_short Salvage radiotherapy for biochemical relapse after complete PSA response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
title_sort salvage radiotherapy for biochemical relapse after complete psa response following radical prostatectomy: outcome and prognostic factors for patients who have never received hormonal therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820601/
https://www.ncbi.nlm.nih.gov/pubmed/17316430
http://dx.doi.org/10.1186/1748-717X-2-8
work_keys_str_mv AT jacintoalexandrea salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT fedeangelobs salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT fagundesliviaa salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT salvajolijoaov salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT castilhomarcuss salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT vianigustavoa salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT fogaroliricardoc salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT novaespauloers salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT pellizzonantoniocassioa salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT maiamariaac salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy
AT ferrignorobson salvageradiotherapyforbiochemicalrelapseaftercompletepsaresponsefollowingradicalprostatectomyoutcomeandprognosticfactorsforpatientswhohaveneverreceivedhormonaltherapy